Inna Demidova, head of regulatory affairs for Russia and CIS at ELC Group, looks at the upcoming regulatory requirements in the world’s fastest growing market.
Stephen Archer of Spring Partnerships looks back on months of M&A buzz in the pharma community, and examines whether the industry really stands to benefit from corporate buyouts.
Money matters: The most cost-effective way to produce pharmaceuticals is to develop an understanding of the critical phases involved, explains Mark Bosley, Purite.
The latest analytical technology to move to the benchtop is nuclear magnetic resonance (NMR) spectroscopy. High-end, high-cost instrumentation has dominated the NMR sector for many years, with both the initial purchase price and annual running...
